Stockreport

Nuvation Bio: A Strong Company Now Fairly Priced [Seeking Alpha]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Ibtrozi's commercial launch is robust, with early patient uptake and revenue run rate supporting a $300–$600 million forward revenue estimate for NUVB. Despite a soli [Read more]